[Syndrome X].
Kotake
Hidetoshi
H
Tohoku CC, Health Care Division, Japan Tobacco Inc.
D000818:Animals; D001629:Bezafibrate / Q000627:therapeutic use; D001645:Biguanides / Q000627:therapeutic use; D005230:Fatty Acids, Nonesterified / Q000502:physiology; D006801:Humans; D006943:Hyperglycemia / Q000209:etiology; D006946:Hyperinsulinism / Q000209:etiology; D006949:Hyperlipidemias / Q000209:etiology; D006973:Hypertension / Q000209:etiology; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D007333:Insulin Resistance; D020738:Leptin / Q000502:physiology; D008019:Life Style; D024821:Metabolic Syndrome / Q000175:diagnosis / Q000209:etiology / Q000628:therapy; D000077205:Pioglitazone; D013844:Thiazoles / Q000627:therapeutic use; D045162:Thiazolidinediones; D014409:Tumor Necrosis Factor-alpha / Q000502:physiology
D001645:Biguanides; D005230:Fatty Acids, Nonesterified; D007004:Hypoglycemic Agents; D000960:Hypolipidemic Agents; D020738:Leptin; D013844:Thiazoles; D045162:Thiazolidinediones; D014409:Tumor Necrosis Factor-alpha; D000077205:Pioglitazone; D001629:Bezafibrate